Brief

The FDA has ended the long-standing shortage of semaglutide and tirzepatide, triggering a crackdown on mass-compounded GLP-1s that are essentially copies of commercially available FDA-approved drugs; compounding is now legally permitted only for specific patients with documented medical needs requiring non-standard doses, forms, or unique indications that are not commercially available [1][2][3]. Companies that continue to mass-produce or market compounded GLP-1s as generic alternatives (such as Hims & Hers and similar telehealth/compounding pharmacies) are facing legal action, seizure, and injunctions for violating FDA policies and making misleading claims [5][7][8]. Who is still operating legally: Legitimate, state-licensed pharmacies and outsourcing facilities that compound GLP-1s strictly under Section 503A or 503B of the FD&C Act for individual patients with a bona fide need for non-standard formulations (e.g., non-standard doses, gummies, sprays, or added ingredients like B12 only if medically justified and not for mass marketing) [1][2][3]. No companies are legally permitted to routinely compound or mass-market GLP-1s that are essentially copies of Ozempic, Wegovy, Mounjaro, or Zepbound once the shortage has ended [3][4][10]. Recommended legal alternatives for patients: FDA-approved injectables: Ozempic and Wegovy (semaglutide) from Novo Nordisk, and Mounjaro and Zepbound (tirzepatide) from Eli Lilly are the only legally guaranteed, FDA-reviewed options for weight loss and diabetes [2][3][6]. Patients should obtain these through licensed prescribers and legitimate pharmacies (e.g., CVS, Walgreens, or local independent pharmacies) that verify supply and do not sell unapproved compounded versions. Brands to avoid for compounded GLP-1s: Hims & Hers, Ro, Brief, and other telehealth platforms that advertise mass-compounded semaglutide or tirzepatide as "generic" or "equivalent" to FDA-approved drugs are now operating illegally and may be subject to FDA enforcement [5][7][8]. The FDA has explicitly stated it will not take action only against compounders filling four or fewer prescriptions per month of essentially copied compounded drugs, but any mass production or marketing is prohibited [2]. Patients seeking weight-loss treatment should prioritize FDA-approved medications over compounded versions to ensure safety, efficacy, and regulatory compliance [3][6][9].

Mentioned in position 7 of 7